Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test

Anesthesiology

Volumn 99, Issue 3, 2003, Pages 701-707

  Yoon, Myung Ha ^a   Choi II, Jeong ^b  

^a Chonnam National University   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHOLINESTERASE INHIBITOR; CLONIDINE; FORMALDEHYDE; NEOSTIGMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; CORNEA REFLEX; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; MALE; MOTOR COORDINATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; CANNABINOIDS; CHOLINESTERASE INHIBITORS; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FORMALDEHYDE; INDOLES; INJECTIONS, SPINAL; MALE; MORPHOLINES; NAPHTHALENES; NEOSTIGMINE; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0041324602     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200309000-00027     Document Type: Article

References (36)

1. Richardson JD, Aanonsen L, Hargreaves KM: Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345:145-53
2. Martin WJ, Loo CM, Basbaum AI: Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999; 82:199-205
3. Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V: Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 2000; 12:2079-86
4. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA: Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001; 93:303-15
5. Gühring H, Schuster J, Hamza M, Ates M, Kotalla CE, Brune K: HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol 2001; 429:127-34
6. Tejwani GA, Rattan AK: Antagonism of antinociception produced by intrathecal clonidine by ketorolac in the rat: The role of the opioid system. Anesth Analg 2000; 90:1152-6
7. Buerkle H, Schapsmeier M, Bantel C, Marcus MA, Wusten R, Van Aken H: Thermal and mechanical antinociceptive action of spinal vs peripherally administered clonidine in the rat inflamed knee joint model. Br J Anaesth 1999; 83:436-41
8. Muerkle H, Boschin M, Marcus MAE, Brodner G, Wusten R, Van Aken H: Central and peripheral analgesia mediated by the acetylcholinesterase-inhibitor nesostigmine in the rat inflamed knee joint model. Anesth Analg 1998; 86: 1027-32
9. Prado WA, Goncalves AS: Antinociceptive effect of intrathecal neostigmine evaluated in rats by two different pain models. Braz J Med Biol Res 1997; 30:1225-31
10. Bouchenafa O, Livingston A: Autoradiographic localisation of α 2 adrenoceptor binding sites in the spinal cord of the sheep. Res Vet Sci 1987; 42:382-5
11. 3H] quinuclidinyl-benzilate binding sites. Brain Res 1985; 345:196-9
12. Hohmann AG, Briley EM, Herkenham M: Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822:17-25
13. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83:393-411
14. Ong WY, Mackie K: A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. J Neurocytol 1999; 28:39-45
15. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR: Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000; 15:510-21
16. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17:1031-6
17. Yoon MH, Yaksh TL: Evaluation of interaction between gabapentin and ibuprofen on the formalin test in rats. ANESTHESIOLOGY 1999; 91:1006-13
18. Tallarida RJ, Murray RB: Manual of pharmacologic calculations with computer programs, 2nd edition. New York, Springer-Verlag, 1987, pp 1-95
19. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature 1998; 394:277-81
20. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS: The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76:189-99
21. Rice AS, Farquhar-Smith WP, Nagy I: Endocannabinoids and pain: Spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002; 66:243-56
22. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-5
23. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE: Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997; 142: 278-87
24. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A: CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93:239-45
25. Mackie K, Hille B: Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992; 89:3825-9
26. 2+ channels in a neuronal expression system. Mol Pharmacol 1996; 49:707-14
27. Twitchell W, Brown S, Mackie K: Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78:43-50
28. Howlett AC, Fleming RM: Cannabinoid inhibition of adenylate cyclase: Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984; 26:532-8
29. Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, Childers SR: Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept Channels 1993; 1:121-34
30. Henry DJ, Chavkin C: Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 1995; 186:91-4
31. Hohmann AG, Martin WJ, Tsou K, Walker JM: Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 1995; 56:2111-8
32. Strangman NM, Walker JM: Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 1999; 82:472-7
33. Berenbaum MC: What is synergy? Pharmacol Rev 1989; 41:93-141
34. Malmberg AB, Yaksh TL: Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. ANESTHESIOLOGY 1993; 79:270-81
35. Roerig SC, Fujimoto JM: Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J Pharmacol Exp Ther 1989; 249:762-8
36. Solomon RE, Gebhart GF: Synergistic antinociceptive interactions among drugs administered to the spinal cord. Anesth Analg 1994; 78:1164-72